Clinical Study
Quantifying the Increase in Radiation Exposure Associated with SPECT/CT Compared to SPECT Alone for Routine Nuclear Medicine Examinations
Table 4
The percentage increase in the effective dose by examination by including the CT.
| | Study type | Average radiopharmaceutical effective dose (mSv) | CT effective dose (mSv) | % increase in effective dose by the inclusion of the CT |
| | 67Gallium | 37.0 | 8.2 | 22% | | 99mTc-MDP | 6.3 | 3.8 | 60% | | 99mTc-MIBI parathyroid | 8.3 | 5.4 | 65% | | 111In-Octreotide | 12.0 | 7 | 58% | | 111In-WBC | 6.7 | 6.4 | 96% | |
Tc99m Ceretec | 6.9 | 15.1 | 219% | | 131I Uptake | 38.5 | 5.6 | 15% | | 131I Posttherapy Scan | 2886.0 | 6.8 | <1% | | 111In Chloride (ProstaScint) | 32.4 | 9.5 | 29% |
|
|
